NCT04312698

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase III Trial to Evaluate the Efficacy and Safety of D013, D326 and D337 Combination Therapy in Dyslipidemia Patients With Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Conditions

• Dyslipidemia Patients With Hypertension

Interventions

Type	Name	Description
DRUG	D013, D326, D337	Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337
DRUG	placebo of D013, D326, D337	Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013
DRUG	D013, placebo of D326, placebo of D337	Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337

Timeline

• Start date: 2019-08-29
• Primary completion: 2021-06-18
• Completion: 2021-06-18
• First posted: 2020-03-18
• Last updated: 2021-07-28

Locations

1 site across 1 country: South Korea